Clinical Trial Update: A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)

View source ↗

Summary

This clinical trial update reports on a study evaluating the integrated dose counter feature on an Albuterol HFA metered-dose inhaler for asthma and COPD, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Bronchitis
• Chronic Obstructive Pulmonary Disease
• Emphysema

Drugs mentioned

• Albuterol HFA MDI (albuterol)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD) | Status: COMPLETED